When it comes to sexual health treatments, why have men historically had more options than women? In this episode of The PG Spot, Dr. Patty Jalomo explores the fascinating and controversial journey of Addyi (flibanserin), the first FDA-approved medication for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

We'll dive into the years-long approval process, the advocacy movement that challenged the FDA, and the debates surrounding safety, efficacy, and gender equity in medicine. Along the way, we'll examine a larger question: Why has women's sexual health research lagged behind men's, and how has that affected treatment options for low desire and sexual dysfunction?

Whether you're a healthcare professional, a woman struggling with low desire, or simply curious about the intersection of science, policy, and sexual health, this episode sheds light on the ongoing effort to close the gap in sexual medicine and ensure that women's sexual well-being receives the attention it deserves.

Join us as we explore the story behind the ”little pink pill” and what it reveals about the future of women's sexual health.

I would love to hear your feedback about today's episode, as well as any questions or topics that you would like addressed in future episodes. Although ”Fanmail” doesn't allow for me to respond back directly, I am happy to address any questions in upcoming episodes. Thank you for listening and taking the time to message The PGspot through Fanmail!

If you want to learn more about sexual health, sexual dysfunction, or how to improve your sex life, follow me on Instagram at @thepgspot or check out my website at doctorpattyj.com for blogs and resources related to sex positivity and real talk about sexuality.  As as always, stay curious, stay empowered, and stay you.